2.Clinical and Laboratory Findings of Nonacute Neurobrucellosis.
Li-Dong JIAO ; Chang-Biao CHU ; Chhetri Jagadish KUMAR ; Jie CUI ; Xian-Ling WANG ; Li-Yong WU ; Cun-Jiang LI ; Xiang-Bo WANG
Chinese Medical Journal 2015;128(13):1831-1833
3.A Case of Toxoplasmic Encephalitis in an Advanced AIDS Patient.
Myoung Ki SIM ; Jeong Ho PARK ; Ho Sung YU ; Kyung Hwa PARK ; Jeom Seok KO ; Woo Kyun BAE ; Jong Hee SHIN ; Sei Jong KIM ; Dong Hyeon SHIN
Korean Journal of Infectious Diseases 2002;34(5):337-340
Toxoplasmic encephalitis (TE) is the most common cause of opportunistic central nervous system infection in advanced acquired immunodeficiency syndrome (AIDS) patients. The incidence of TE has fallen markedly after the availability of highly active antiretroviral therapy and cotrimoxazole chemoprophylaxis. TE linked to AIDS is a rare entity in Korea, but we must consider TE in the differential diagnosis of the opportunistic infections in AIDS patients. We report a case of toxoplasmic encephalitis in an advanced AIDS patient presenting as progressive right facial palsy.
Acquired Immunodeficiency Syndrome
;
Antiretroviral Therapy, Highly Active
;
Central Nervous System Infections
;
Chemoprevention
;
Diagnosis, Differential
;
Encephalitis*
;
Facial Paralysis
;
Humans
;
Incidence
;
Korea
;
Opportunistic Infections
;
Trimethoprim, Sulfamethoxazole Drug Combination
4.Central nervous system infection caused by Exophiala dermatitidis in a case and literature review.
Bing HU ; Shaoying LI ; Huili HU ; Tianming CHEN ; Xin GUO ; Zhixiao ZHANG ; Fang DONG ; Zheng LI ; Quan WANG ; Kaihu YAO ; Gang LIU
Chinese Journal of Pediatrics 2014;52(8):620-624
OBJECTIVETo summarize the clinical features, imaging characteristics, diagnosis and treatment of a case with central nervous system infection caused by Exophiala dermatitidis, as well as to review the related literature.
METHODAssociated literature and clinical data of an 8-year-old boy who was diagnosed as central nervous system infection caused by Exophiala dermatitidis in Beijing Children's Hospital Affiliated to Capital Medical University and hospitalized twice from 2012 to 2014 were analyzed retrospectively.
RESULTThe boy was 8 years old with the chief complaint of dizziness for 2 months, intermittent fever for 1 month accompanied with spasm twice. He was diagnosed as bile ducts space-occupying lesions 2 years ago, when the pathological diagnosis was fungal infection. The boy was treated with irregular anti-fungal therapy. Then the boy developed nervous symptoms, impaired consciousness and abnormal physical activity that developed gradually. After hospitalization the cerebral MRI of the boy showed space-occupying lesions accompanied with edema of surrounding area. Filamentous fungi was found by brain biopsy, which was culture positive for Exophiala dermatitidis. After diagnosis the boy was treated with amphotericin B (AMB), voriconazole and 5-Fu, as well as symptomatic treatment. The state of the boy was improved gradually. Two months later, the boy could communicate with others normally and move personally. The lesions and edema seen on the MRI was decreased moderately. Accordingly, the boy was treated with oral voriconazole maintenance treatment for about 1 year and 4 months after discharge. During this period, the state of him was stable without symptoms. The lesions shown by MRI did not disappear but decreased on regular examination. However, recently the disease of the boy progressed again, with dizziness, neck pain, headache and progressive nervous symptoms (intermittent spasm, inability to cough, and impaired consciousness). The boy died at last, even with the active treatment at the second hospitalization. Exophiala dermatitidis was culture-positive again in his CSF, and was confirmed by PCR successfully.
CONCLUSIONThe central nervous system infection caused by Exophiala dermatitidis is rare. Clinical features of this disease were similar to those of other fungal CNS infection, cerebral MRI of which could show the similar lumpy lesions. Diagnosis of the disease should be based on pathology and culture.
Amphotericin B ; administration & dosage ; Antifungal Agents ; administration & dosage ; Brain ; diagnostic imaging ; microbiology ; pathology ; Central Nervous System Infections ; diagnosis ; drug therapy ; microbiology ; Cerebrospinal Fluid ; microbiology ; Child ; Drug Therapy, Combination ; Exophiala ; isolation & purification ; Fatal Outcome ; Fluorouracil ; administration & dosage ; Humans ; Magnetic Resonance Imaging ; Male ; Mycoses ; diagnosis ; drug therapy ; microbiology ; Radiography ; Voriconazole ; administration & dosage
5.Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Huan XIA ; Xiao-Jie HUANG ; Yue HU ; Li-Ying GAO ; Yue WU ; Hao WU ; Zhong-Fang YAN ; Ping MA
Chinese Medical Journal 2021;134(23):2850-2856
BACKGROUND:
Central nervous system (CNS) symptoms after efavirenz (EFV) treatment in people living with human immunodeficiency virus (HIV) could persist and impact their quality of life. We assessed the impact of EFV-based regimen replacement with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), which is considered an alternative option for subjects who do not tolerate EFV. Most specifically, we assessed the safety and the efficacy of E/C/F/TAF and its effects on the participants' neuropsychiatric toxicity symptoms in a real-life setting.
METHODS:
A prospective cohort study was conducted among virologic suppressed HIV-positive participants receiving EFV-based regimens with ongoing CNS toxicity ≥ grade 2. The participants were switched to single-pill combination regimens E/C/F/TAF and followed up for 48 weeks. The neuropsychiatric toxicity symptoms were measured using a CNS side effects questionnaire, as well as the Hospital Anxiety and Depression Scale and the Pittsburgh Sleep Quality Index. The primary outcome measure was the proportion of participants experiencing grade 2 or higher CNS toxicity after EFV switch off at weeks 12, 24, and 48. Secondary endpoints included virologic and immunological responses and the effect on fasting lipids at week 48 after switch.
RESULTS:
One hundred ninety-six participants (96.9% men, median age: 37.5 years, median: 3.7 years on prior EFV-containing regimens) were included in the study. Significant improvements in anxiety and sleep disturbance symptoms were observed at 12, 24, and 48 weeks after switching to E/C/F/TAF (P < 0.05). No significant change in depression symptom scores was observed. At 48 weeks after switch, HIV viral load <50 copies/mL was maintained in all of the participants, median fasting lipid levels were moderately increased (total cholesterol [TC]: 8.2 mg/dL, low-density lipoprotein cholesterol [LDL-C]: 8.5 mg/dL, high-density lipoprotein cholesterol [HDL-C]: 2.9 mg/dL, and triglyceride (TG): 1.6 mg/dL, and the TC:HDL-C ratio remained stable.
CONCLUSIONS
The single-pill combination regimens E/C/F/TAF is safe and well tolerated. This study reveals that switching from EFV to E/C/F/TAF significantly reduces neuropsychiatric toxicity symptoms in people living with HIV with grade 2 or higher CNS complaints.
Adenine/therapeutic use*
;
Adult
;
Alanine
;
Alkynes
;
Anti-HIV Agents/adverse effects*
;
Benzoxazines
;
Central Nervous System
;
Cobicistat/therapeutic use*
;
Cyclopropanes
;
Drug Combinations
;
Emtricitabine/therapeutic use*
;
Female
;
HIV Infections/drug therapy*
;
Humans
;
Male
;
Prospective Studies
;
Quality of Life
;
Quinolones
;
Sleep Quality
;
Tenofovir/analogs & derivatives*
6.Neurologic Manifestations of Enterovirus 71 Infection in Korea.
Kyung Yeon LEE ; Myoung Sook LEE ; Dong Bin KIM
Journal of Korean Medical Science 2016;31(4):561-567
Enterovirus 71 frequently involves the central nervous system and may present with a variety of neurologic manifestations. Here, we aimed to describe the clinical features, magnetic resonance imaging (MRI) findings, and cerebrospinal fluid (CSF) profiles of patients presenting with neurologic complications of enterovirus 71 infection. We retrospectively reviewed the records of 31 pediatric patients hospitalized with acute neurologic manifestations accompanied by confirmed enterovirus 71 infection at Ulsan University Hospital between 2010 and 2014. The patients' mean age was 2.9 ± 5.5 years (range, 18 days to 12 years), and 80.6% of patients were less than 4 years old. Based on their clinical features, the patients were classified into 4 clinical groups: brainstem encephalitis (n = 21), meningitis (n = 7), encephalitis (n = 2), and acute flaccid paralysis (n = 1). The common neurologic symptoms included myoclonus (58.1%), lethargy (54.8%), irritability (54.8%), vomiting (48.4%), ataxia (38.7%), and tremor (35.5%). Twenty-five patients underwent an MRI scan; of these, 14 (56.0%) revealed the characteristic increased T2 signal intensity in the posterior region of the brainstem and bilateral cerebellar dentate nuclei. Twenty-six of 30 patients (86.7%) showed CSF pleocytosis. Thirty patients (96.8%) recovered completely without any neurologic deficits; one patient (3.2%) died due to pulmonary hemorrhage and shock. In the present study, brainstem encephalitis was the most common neurologic manifestation of enterovirus 71 infection. The characteristic clinical symptoms such as myoclonus, ataxia, and tremor in conjunction with CSF pleocytosis and brainstem lesions on MR images are pathognomonic for diagnosis of neurologic involvement by enterovirus 71 infection.
Acute Disease
;
Brain/diagnostic imaging
;
Central Nervous System Diseases/etiology/*pathology
;
Child
;
Child, Preschool
;
Encephalitis/pathology
;
Enterovirus A, Human/genetics/*isolation & purification
;
Enterovirus Infections/drug therapy/*pathology/virology
;
Feces/virology
;
Female
;
Humans
;
Immunoglobulins/administration & dosage
;
Infant
;
Injections, Intravenous
;
Leukocytes/cytology
;
Leukocytosis/cerebrospinal fluid/pathology
;
Magnetic Resonance Imaging
;
Male
;
RNA, Viral/genetics/metabolism
;
Real-Time Polymerase Chain Reaction
;
Republic of Korea
;
Retrospective Studies
;
Seasons